GlassScriptPhysician profile
David E Brown
NPI 1679507065
$1,247.39
in general payments reported to CMS, 2019-2025
20 companies · $492 in 2025
The $492 reported for 2025 was more than what 78% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.77 · 2020: $107 · 2021: $14.02 · 2022: $104 · 2023: $122 · 2024: $396 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771 · Education: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.20 |
| Education | $238.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $308.95 | 2024-2025 | |
| Amgen INC. | $155.33 | 2024-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $139.19 | 2022-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $95.70 | 2023-2025 | Tezspire, Fasenra |
| Baxter Healthcare | $75.14 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $69.15 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $63.00 | 2020-2021 | |
| Medtronic Vascular, INC. | $58.03 | 2020 | |
| Pharming Healthcare, INC. | $57.94 | 2023-2025 | Ruconest |
| Azurity Pharmaceuticals, INC. | $43.10 | 2025 | Alvesco |
| Genzyme Corporation | $38.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.41 | 2024 | Cuvitru |
| Electromed, INC. | $20.94 | 2024 | Smartvest |
| Glaxosmithkline, LLC. | $18.27 | 2022 | |
| Abbvie INC. | $16.58 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $15.96 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $15.92 | 2025 | Lumryz |
| Gilead Sciences, INC. | $14.98 | 2022 | |
| Merck Sharp & Dohme LLC | $12.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.